left ventricular ejection

Related by string. Left ventricular ejection * lefts . LEFT . Lefts : No Child Left . left arm spinner . ruling Left Front / Ventricular : ventricular assist device . ventricular septal defect . ventricular fibrillation VF / ejections . Ejection . Ejections : CAUTIONS AND EJECTIONS YC . preserved ejection fraction . CAUTIONS AND EJECTIONS Officials * Left Ventricular Ejection Fraction *

Related by context. All words. (Click for frequent words.) 73 LVEF 70 ejection fraction 70 left ventricular systolic 68 Left ventricular ejection 65 left ventricular dysfunction 65 ejection fractions 64 fraction LVEF 63 NYHA class 62 systolic dysfunction 62 preserved ejection fraction 62 ventricular function 61 diastolic dysfunction 61 NYHA functional class 61 infarct size 61 diastolic heart 61 systolic function 61 serum calcium levels 61 pulmonary capillary wedge 61 HbA1c levels 61 echocardiographic 61 CK MB 60 serum creatinine levels 60 FEV1 60 liver histology 60 MACCE 60 PSADT 60 revascularization procedures 60 β blockers 59 hsCRP levels 59 myocardial infarction 59 baseline HbA1c 59 glomerular filtration rate 59 repeat revascularization 59 ischemic cardiomyopathy 59 troponin T 59 undergoing coronary artery 59 multivessel disease 58 eGFR 58 diastolic function 58 Ejection Fraction 58 coronary revascularization 58 morphometric vertebral fractures 58 laboratory abnormalities 58 myocardial infarction MI 58 systolic 58 atheroma volume 58 HbA 1c 58 estimated glomerular filtration 58 QRS duration 58 cardiovascular mortality 58 alanine aminotransferase 58 hemoglobin A1c levels 58 neutrophil counts 58 proteinuria 58 #mmHg [001] 58 thrombotic events 58 intima media thickness 58 macrovascular 58 NYHA Class II 58 thromboembolic events 57 left ventricular LV 57 mitral regurgitation 57 NYHA 57 fasting insulin 57 thromboembolic 57 CABG 57 myocardial infarctions 57 microvascular complications 57 reinfarction 57 myocardial ischemia 57 sUA 57 glomerular filtration 57 lumbar spine bone 57 fasting plasma glucose 57 aminotransferases 57 creatinine clearance 57 serum potassium 57 renal function 57 hypertensives 57 carotid IMT 57 renal impairment 57 serum phosphate 57 serum creatinine 57 ATACAND 57 albuminuria 57 serum urate 57 NATRECOR R 57 myocardial infarction stroke 57 serum sodium 57 renal dysfunction 56 left ventricular hypertrophy 56 serum calcium 56 LV dysfunction 56 tolvaptan 56 biochemical recurrence 56 HOMA IR 56 cTnT levels 56 candesartan cilexetil 56 periprocedural 56 alteplase 56 Left Ventricular Ejection Fraction 56 dapagliflozin plus 56 protein excretion 56 discontinuations due 56 occlusive disease 56 contractile function 56 serum uric acid 56 Index CDAI 56 leukocyte count 56 asymptomatic carotid stenosis 56 nicardipine 56 P = .# 56 mL/min/#.# m 2 56 lumbar spine BMD 56 hip BMD 56 rosuvastatin #mg 56 serum triglycerides 56 glycated hemoglobin levels 56 reoperation 56 A1C levels 56 revascularization 56 dyssynchrony 56 bypass grafting 56 erectile function 56 TAXUS Express Stent 56 #.#/#.# mmHg [001] 56 FOLFOX4 56 PASI scores 56 hydroxyvitamin D levels 56 binary restenosis 56 ventricular ejection fraction 56 infarctions 56 lipid lowering therapy 55 aspartate aminotransferase AST 55 lactate dehydrogenase LDH 55 nondiabetic patients 55 MELD scores 55 pericardial effusion 55 elevated triglycerides 55 glycosylated hemoglobin HbA1c 55 triglyceride levels 55 carotid stenosis 55 CrCl 55 hypoperfusion 55 systolic BP 55 antihypertensive therapy 55 Proteinuria 55 composite endpoint 55 hemodynamics 55 candesartan 55 SUVmax 55 A1c levels 55 bypass graft CABG surgery 55 serum phosphate levels 55 NYHA Class III 55 microvascular disease 55 exhaled nitric oxide 55 creatinine levels 55 ejection fraction EF 55 ventricular tachyarrhythmia 55 mm Hg systolic 55 mm Hg 55 cytopenias 55 echocardiographic parameters 55 perioperative mortality 55 systolic hypertension 55 postoperative mortality 55 LV ejection fraction 55 eplerenone 55 virologic response 55 platelet inhibition 55 pCR 55 antihypertensive medications 55 nonischemic 55 NIHSS 55 recurrent ischemia 55 MADRS score 55 patients undergoing CABG 55 endometrial thickness 55 nondiabetics 55 postoperative complications 55 kidney function 55 tirofiban 55 diastolic blood pressures 55 gadolinium enhancing lesions 55 renal insufficiency 55 cTnT 55 intracerebral hemorrhage 55 HDRS 55 XIENCE V PROMUS Stent 55 definite stent thrombosis 55 sinus rhythm 55 CYPHER Stent 55 retinal thickness 55 platelet reactivity 55 hypogonadal men 55 troponins 55 pulmonary exacerbations 55 reintervention 55 Thrombolysis 55 sweat chloride 55 serum cholesterol 55 alanine aminotransferase ALT 55 plasma creatinine 55 QTcF 55 serum phosphorus 54 leukopenia 54 Crohn Disease Activity 54 hemoglobin A1c HbA1c 54 thromboembolic complications 54 cardiogenic shock 54 serum urate levels 54 #mg/dL [001] 54 stable angina 54 lymph node involvement 54 microalbuminuria 54 nonfasting triglycerides 54 VT VF 54 unstable angina pectoris 54 creatinine ratio 54 plasma glucose levels 54 fasting plasma glucose FPG 54 electrocardiographic 54 intraocular pressure IOP 54 SGRQ 54 symptomatic VTE 54 mIU L 54 refractory ischemia 54 cardiac dysfunction 54 diameter stenosis 54 cerebral infarction 54 gout flares 54 thromboembolism 54 aortic regurgitation 54 urinary albumin 54 fasting blood glucose 54 atypical hyperplasia 54 NATRECOR ® 54 lung metastasis 54 macroalbuminuria 54 left ventricular diastolic 54 elevated ALT 54 cTnI 54 evaluable 54 cerebrovascular events 54 atherosclerotic lesions 54 serum clusterin levels 54 hemolysis 54 IIIa inhibitor 54 Events MACE 54 postoperative complication 54 revascularizations 54 fractional shortening 54 CD4 + cell 54 mL min 54 decompensated heart failure 54 mmHg diastolic 54 nmol L 54 multivariable analysis 54 serum PSA 54 LDL C 54 QTc interval 54 nonfasting triglyceride levels 54 metformin monotherapy 54 serum glucose 54 acute myocardial infarction AMI 54 Secondary efficacy endpoints 54 serum vitamin D 54 reperfusion therapy 54 NPH insulin 54 platelet aggregation 54 advanced adenomas 54 platelet counts 54 prednisone prednisolone 54 triglyceride concentrations 54 Doxil ® 54 myocardial perfusion 54 CABG surgery 54 blood Phe levels 54 HIV RNA 54 azacitidine 54 hsCRP 54 serum IGF 54 perioperative complications 54 primary percutaneous coronary 54 homocysteine levels 54 beta blocker therapy 54 rFVIIa 54 noncardiac 54 moderate renal impairment 54 atherogenic dyslipidemia 54 tenecteplase 54 calculated creatinine clearance 54 valvular disease 54 #Gy 54 OPCAB 54 squamous histology 54 preintervention 54 nonfatal MI 54 achieved ACR# 54 NIHSS score 54 preserved systolic 54 fasting glucose levels 54 carotid artery stenosis 54 LVSD 54 NT proBNP 54 nonobstructive CAD 54 HbA 1c levels 54 paclitaxel eluting stents 54 troponin 53 serum testosterone 53 carotid plaque 53 Serum creatinine 53 mineral density 53 endothelial function 53 neointimal hyperplasia 53 baseline serum creatinine 53 elevated triglyceride levels 53 thrombotic complications 53 recurrent VTE 53 arterial stiffness 53 transaminases 53 diastolic BP 53 prospectively defined 53 lopinavir r arm 53 deep venous thromboses 53 lipid parameters 53 imatinib therapy 53 urinary oxalate 53 DMARD 53 acute myocardial infarction 53 HDL C 53 coronary stenosis 53 achieved statistical significance 53 lactate dehydrogenase 53 thyroglobulin 53 luminal diameter 53 glycated hemoglobin 53 renal artery stenosis 53 angiotensin II receptor blockers 53 ventricular mass 53 PaO 2 53 serum concentrations 53 radical nephrectomy 53 Primary endpoints 53 fasting triglyceride levels 53 bosentan 53 everolimus eluting stents 53 CABG coronary artery 53 non valvular atrial 53 nesiritide 53 urinary N telopeptide 53 locoregional recurrence 53 EBRT 53 mRNA expression 53 ventricular arrhythmias 53 vertebral fracture 53 postoperative pulmonary 53 advanced adenoma 53 creatine kinase 53 abciximab 53 acutely decompensated congestive heart 53 hematologic toxicity 53 angiotensin converting enzyme 53 serum phosphorous 53 secondary endpoint 53 atrioventricular block 53 colorectal liver metastases 53 ischemia driven 53 Kaplan Meier analysis 53 tHcy 53 aortic insufficiency 53 locoregional 53 μg L 53 endoscopic remission 53 diastolic pressures 53 glulisine 53 dobutamine 53 certolizumab 53 severe neutropenia 53 biochemical relapse 53 urine NGAL 53 functional mitral regurgitation 53 Lp PLA2 53 reperfusion 53 angioplasty stenting 53 aminotransferase ALT 53 ivabradine 53 serum ferritin 53 aspirin beta blockers 53 ipsilateral stroke 53 SCr 53 LV hypertrophy 53 hypokalemia 53 coronary calcification 53 mitral stenosis 53 arterial thromboembolic events 53 severe renal impairment 53 cardiovascular hospitalizations 53 histologic 53 #.#mmol L [002] 53 afterload 53 hypertensive patients 53 ventricular dilatation 53 Systolic 53 mm Hg diastolic 53 cystatin C 53 lymphopenia 53 aldosterone antagonists 53 subclinical hypothyroidism 53 % Confidence Interval 53 oral antidiabetic medication 53 #mmHg [002] 53 plasma triglycerides 53 fosamprenavir 53 MetS 53 plus methotrexate 53 hypercholesterolemia 53 HIV HCV coinfected 53 aspartate aminotransferase 53 lipid levels 53 PCWP 53 Taxus Stent 53 creatine kinase MB 53 hypogonadal 53 serum estradiol 53 RYGB 53 cardiac resynchronization 53 infarcts 53 losartan 53 NSTE ACS 53 bezafibrate 53 Microalbuminuria 53 adiponectin concentrations 53 BENICAR HCT 53 C Reactive Protein 53 Ishak fibrosis score 53 corrected QT interval 53 tumor recurrence 52 steatosis 52 BH4 52 systemic embolism 52 antiarrhythmic drug 52 HNSCC 52 virologic failure 52 HSCT 52 dose atorvastatin 52 ventricular dilation 52 serum prostate 52 ng dL 52 umol L 52 elevated creatinine 52 carotid artery stenting CAS 52 oral hypoglycemic agents 52 ischemic 52 C reactive protein 52 amnestic mild cognitive impairment 52 pressor response 52 GFR 52 normotensive 52 abdominal circumference 52 posttransplant 52 onset atrial fibrillation 52 STEMI patients 52 oxycodone CR 52 postoperative hemorrhage 52 undergoing CABG 52 lung function 52 albumin excretion rate 52 underwent coronary angiography 52 carotid intima media 52 T2DM 52 silent ischemia 52 plasma glucose 52 peptide BNP 52 HbA 1C 52 radial artery grafts 52 hypophosphatemia 52 cardioembolic stroke 52 thrombolytic therapy 52 nonfatal stroke 52 TAXUS Stent 52 density lipoprotein cholesterol 52 preoperative PSA 52 angiotensin converting enzyme inhibitors 52 postdose 52 distensibility 52 baseline A1C 52 atherosclerotic disease 52 nonfatal myocardial infarction 52 lispro 52 valvular 52 macrovascular disease 52 aldosterone 52 parenchymal 52 glycated hemoglobin HbA1c 52 eosinophil count 52 statin therapy 52 Hb A1C 52 % CI #.#-#.# [003] 52 ALLHAT 52 paroxysmal AF 52 underwent angiography 52 ICDs implanted 52 radiotherapy RT 52 reoperations 52 Subgroup analysis 52 CI -#.# 52 pneumonectomy 52 atrioventricular valve 52 myocardial 52 AST ALT 52 trough FEV1 52 parathyroidectomy 52 stenoses 52 mild renal insufficiency 52 graft occlusion 52 microbleeds 52 univariate analysis 52 cardiac biomarkers 52 atrial 52 telmisartan 52 multivariable adjusted 52 #mm Hg 52 bone resorption 52 Thiazolidinediones 52 defibrillator CRT D 52 thrombocytopenic 52 coronary artery disease 52 cholesterol LDL C 52 myocardial reperfusion 52 reach statistical significance 52 elevated LDL cholesterol 52 highest tertile 52 intact parathyroid hormone 52 Psoriasis Area 52 teriflunomide 52 pulmonary artery banding 52 adrenalectomy 52 Zometa hazard 52 primary aldosteronism 52 colorectal adenoma 52 gastric pH 52 nonvertebral fracture 52 TACE 52 inotropic 52 Fonarow 52 revascularisation 52 median PFS 52 % CI #.#-#.# [005] 52 salivary flow 52 lymphocyte counts 52 vWF 52 bone marrow reticulin 52 bradycardia 52 hs CRP 52 CVD mortality 52 glycoprotein IIb IIIa inhibitors 52 isoprostane 52 liver transaminases 52 tiotropium 52 flow mediated dilation 52 valsartan 52 mixed hyperlipidemia 52 serum PTH 52 Diastolic 52 overt nephropathy 52 subtrochanteric 52 carotid endarterectomy CEA 52 sFlt 1 52 MMSE scores 52 euthyroid 52 carotid artery intima media 52 RVOT 52 hematological parameters 52 tumor progression TTP 52 aldosterone antagonist 52 acute decompensation 52 symptomatic intracerebral hemorrhage 52 intraocular pressure 52 prespecified secondary 52 resynchronization therapy 52 statistically significant p 52 dysfunction LVSD 52 salpingo oophorectomy 52 postoperative AF 52 dalteparin 52 Albuminuria 52 lipoprotein 52 LDL cholesterol levels 52 UPDRS motor 52 #.#ng/ml 52 angina chest 52 endophthalmitis 52 FluCAM arm 52 EDARBI 52 carotid endarterectomy 52 Fasting blood glucose 52 brachial artery flow 52 stenosis 52 pT3 52 platelet function 52 D dimer 52 dose cytarabine 52 REYATAZ r arm 52 fibrinolytic 52 Unified Parkinson Disease 52 placebo dexamethasone 52 Renal dysfunction 52 narrow QRS 51 virologic responses 51 p = #.# [002] 51 urate levels 51 infarct 51 ULORIC 51 transaminase elevations 51 plasma concentrations 51 obstructive CAD 51 macrovascular events 51 parathyroid carcinoma 51 underwent CABG 51 HAQ DI 51 nonoperative 51 hippocampal volume 51 hemodynamically significant 51 clazosentan 51 p = .# [002] 51 angiographic restenosis 51 Unstable Angina 51 cardiovascular morbidity 51 blood urea nitrogen 51 UACR 51 EDSS score 51 cardiac resynchronisation therapy 51 IABP 51 paricalcitol 51 transferrin saturation 51 dyslipidaemia 51 Complication rates 51 incontinence episodes 51 carotid artery thickness 51 patients undergoing percutaneous 51 QTc 51 β blocker 51 neurologic outcomes 51 ketorolac 51 QTc prolongation 51 stented 51 51 serum albumin 51 fasting glucose 51 myocardial necrosis 51 endarterectomy 51 benazepril 51 confirmed thrombotic cardiovascular 51 NYHA Class 51 Insulin sensitivity 51 log# copies mL 51 x ULN 51 thyroid stimulating hormone 51 SGOT 51 subclinical hyperthyroidism 51 endometrial carcinoma 51 activated partial thromboplastin 51 coronary artery bypass grafting 51 Acute Myocardial Infarction 51 secondary efficacy endpoint 51 TAXUS stent 51 Postoperative 51 glycosylated hemoglobin 51 Erythropoietic therapies may 51 myeloperoxidase 51 nonresponders 51 coronary intervention 51 mediated dilation 51 splenectomized patients 51 Multivariate analyzes 51 fibrinolytic therapy 51 severe mitral regurgitation 51 elevated hsCRP 51 QTc intervals 51 hyperphenylalaninemia HPA due 51 #.#mmHg 51 serum lipid levels 51 airflow obstruction 51 colectomy 51 rate variability HRV 51 DAPT 51 QT interval 51 concomitant medications 51 extrapyramidal symptoms 51 eptifibatide 51 AVANDIA 51 Major Adverse Cardiac 51 neurologic progression 51 uncontrolled hypertension 51 CHD mortality 51 ischemic stroke 51 hemoglobin A1c 51 mL/min/#.# m2 51 NNT = 51 hypopneas 51 specific antigen PSA 51 unfractionated heparin 51 cryptogenic stroke 51 oral FTY# 51 histological subtype 51 aminotransferase levels 51 resected pancreatic cancer 51 ventricular 51 CI #.#-#.# [001] 51 breast cancer recurrence 51 myocardial infarct 51 NSTEMI 51 natriuretic peptides 51 cirrhotic patients 51 statistically significant p = 51 antiplatelet drugs 51 pulmonary artery pressures 51 creatinine 51 cardiac troponin 51 sirolimus eluting stents 51 postoperatively 51 thiazide diuretic 51 cerebral perfusion 51 HMG CoA reductase inhibitors 51 hemodynamic 51 albumin creatinine ratio 51 μmol L 51 Val HeFT 51 nephropathy 51 fluvastatin 51 relapsed MM 51 angiotensin receptor blockers 51 mitral insufficiency 51 receiving VICTRELIS 51 CYPHER ® Stent 51 telomere lengths 51 WOMAC scores 51 Cypher Stent 51 mechanical dyssynchrony 51 hyperglycaemia 51 complete cytogenetic response 51 vessel occlusion 51 glycemia 51 TAXUS p value 51 mU liter 51 nadolol 51 Baseline characteristics 51 serum cortisol 51 ventricular fibrillation VF 51 cardiac perfusion 51 elevated LDH 51 pulmonary artery pressure 51 events AEs 51 Montgomery Asberg Depression 51 -#.# mg dL [002] 51 plasma lipids 51 Pioglitazone 51 events MACE 51 noncardiac surgery 51 ADHF 51 magnesium intake 51 urate lowering therapy 51 allopurinol 51 IOP lowering 51 aspirin heparin 51 hydroxyvitamin D 51 pulsatile flow 51 HRQOL 51 advanced neoplasia 51 fatal myocardial infarction 51 generalized edema 51 pancytopenia 51 Secondary endpoints 51 HbA1C 51 abnormal glucose tolerance 51 annualized relapse 51 lipid lowering agents 51 revascularization procedure 51 ARIXTRA 51 prespecified 51 lymph node metastasis 51 RBP4 51 Endothelial function 51 mammographic density 51 ABCB1 51 nephrotoxicity 51 CMV disease 51 microvascular 51 EDSS scores 51 distant metastases 51 free survival PFS 51 intravenous diuretics 51 hormone therapy estrogen 51 SHBG levels 51 partial remissions 51 XIENCE V vs. 51 atherothrombotic events 51 apo B 51 nondiabetic 51 plasma urate 51 PSA nadir 51 acute STEMI 51 QT intervals 51 thyrotropin levels 51 prolonged QT interval 51 serum HCV RNA 51 antihypertensive drugs 51 KIF6 carriers 51 hemoglobin A1C 51 symptomatic carotid stenosis 50 HER2 expression 50 gestational hypertension 50 atherothrombosis 50 hepatocellular carcinomas 50 HBeAg seroconversion 50 TNF antagonist 50 inflammatory biomarkers 50 rehospitalization 50 coronary interventions 50 hypercalcemia 50 metastatic malignant 50 cardiac resynchronization therapy 50 dizziness nausea diarrhea 50 cardiopulmonary bypass 50 density lipoprotein HDL cholesterol 50 torsades de pointes 50 HbA1c 50 stratifying patients 50 TURBT 50 oophorectomy 50 prognostic significance 50 GERD symptom 50 clinico pathological 50 plasma renin activity 50 liver transplant recipients 50 g dL 50 pg mL 50 vertebral fractures 50 metabolic parameters 50 XIENCE V demonstrated 50 revascularized 50 N telopeptide 50 platelet activation 50 locoregional disease 50 ertapenem 50 sustained virologic response 50 target lesion revascularization 50 recurrent coronary 50 Percutaneous Coronary Intervention 50 lipid lowering drugs 50 HDL cholesterol 50 LV systolic dysfunction 50 nonischemic cardiomyopathy 50 hepatic enzymes 50 intravascular hemolysis 50 alkaline phosphatase 50 Ki# 50 angiographically 50 MS relapses 50 rosuvastatin Crestor 50 Carotid Revascularization Endarterectomy vs. 50 serum LDL cholesterol 50 GnRH agonist 50 prognostic factors 50 haemodynamic 50 primary efficacy endpoint 50 adalimumab 50 mitral regurgitation MR 50 ventricular tachycardia VT 50 Operative mortality 50 preoperatively 50 impaired renal 50 ARB telmisartan 50 peak VO2 50 impaired endothelial 50 recanalization 50 CCyR 50 radioiodine therapy 50 vascular inflammation 50 ramipril 50 clinically meaningful improvement 50 target vessel revascularization 50 BENICAR 50 6MWD 50 primary hypercholesterolemia 50 fibrinolysis 50 Atherosclerotic 50 endometrial hyperplasia 50 cystectomy 50 Rasilez Tekturna 50 mg simvastatin 50 CR CRu 50 cerebral ischemia 50 tertile 50 DES implantation 50 dyspnea 50 CLA supplementation 50 hyperkalemia 50 hemoglobin concentrations 50 ischemia 50 contrast induced nephropathy 50 mEq L 50 lymphadenectomy 50 Stent thrombosis 50 coagulation parameters 50 HRQL 50 transthoracic 50 cilostazol 50 invasive coronary angiography 50 severe exacerbations 50 perioperatively 50 Median survival 50 cerebral vasospasm 50 placebo p 50 tamsulosin 50 postintervention 50 IFN α 50 enoxaparin 50 International Normalized Ratio 50 acute myocardial infarction MI 50 thrombolytic agents 50 receiving VELCADE 50 serum ALT 50 residual platelet reactivity 50 severe hypoglycemia 50 peri procedural 50 PLX STROKE targeting 50 varices 50 unstable angina UA 50 postoperative morbidity 50 dosage regimens 50 serum aminotransferase levels 50 dose colchicine 50 neurocognitive function 50 artery stenosis 50 VADT 50 anemia hemoglobin 50 irbesartan 50 ACE inhibitors 50 RBP4 levels 50 mmHg systolic 50 neostigmine 50 retransplantation 50 BRCA1 mutation carriers 50 OAB symptoms 50 Triglyceride levels 50 PAOD 50 colorectal adenomas 50 Ischemic 50 mg dL 50 aortic stenosis 50 intermittent claudication 50 metoprolol tartrate 50 mmol L 50 #/#mmHg 50 febrile neutropenia 50 MMSE score 50 adrenal insufficiency 50 serum leptin 50 angioplasties stents 50 adenotonsillectomy 50 elective PCI 50 ICD implants 50 mucosal healing 50 asystole 50 diastolic blood pressure 50 inotropic agents 50 total cholesterol triglycerides 50 daunorubicin 50 blood Phe 50 systolic blood pressures 50 detrusor overactivity 50 wound dehiscence 50 autonomic dysfunction 50 -#.# mmHg 50 VEGF expression 50 saphenous vein grafts 50 statistically nonsignificant 50 idraparinux 50 postprocedure 50 antigen PSA levels 50 S#A# [002] 50 mg/m2 dose 50 glycosylated hemoglobin levels 50 anticoagulation 50 hemodynamic parameters 50 mg BID 50 leucopenia 50 ventricular remodeling 50 coronary artery bypass 50 VTEs 50 hepatic function 50 arterial oxygen saturation 50 serum testosterone levels 50 cholecystectomy 50 clodronate 50 HBeAg negative patients

Back to home page